SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-062367
Filing Date
2024-05-20
Accepted
2024-05-20 16:01:38
Documents
88
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sabs-20240331.htm   iXBRL 10-Q 1882069
2 EX-31.1 sabs-ex31_1.htm EX-31.1 22236
3 EX-31.2 sabs-ex31_2.htm EX-31.2 22417
4 EX-32.1 sabs-ex32_1.htm EX-32.1 9621
5 EX-32.2 sabs-ex32_2.htm EX-32.2 9957
6 GRAPHIC img153674639_0.jpg GRAPHIC 35752
  Complete submission text file 0000950170-24-062367.txt   9933413

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20240331.xsd EX-101.SCH 1738306
92 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20240331_htm.xml XML 1692519
Mailing Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104
Business Address 2100 EAST 54TH STREET NORTH SIOUX FALLS SD 57104 605-679-6980
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39871 | Film No.: 24964301
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)